Biologic agents are designed to inhibit key pathogenic steps, providing therapeutic benefit for the treatment of psoriasis. Dermatology nurses must be prepared to integrate biologic agents into ...

Age at initiation of treatment and the type of biologic therapy prescribed effect the rate of drug survival among patients with psoriasis.

Based on these observations, many new biologic therapies to treat psoriasis are now in development. These agents, developed primarily through recombinant DNA techniques, are designed to target T ...

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

Nevertheless, 68% of the $3.5 billion global psoriasis market is captured by biologic therapies; topical agents and conventional systemic drugs account for ∼25% and ∼7%, respectively.

Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

Biologics often help when other treatments haven’t worked to treat psoriasis. They’re synthetic versions of proteins created from human cells that target specific parts of your immune system.

Though much is still unknown about psoriasis, experts believe it could ... Treatments include phototherapy, steroids, topicals, and newer biologic agents which suppress the immune response.

These findings may offer more personalized treatment and prevention recommendations for patients with psoriasis.

Immunosuppressive agents prevent an effective immune ... but they still recommend vaccination. People with psoriasis should continue their current biologic or immunosuppressive therapy when ...